VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Immune escape is a prerequisite for tumor development. To avoid the immune system, tumors develop different mechanisms, including T cell exhaustion, which is characterized by expression of immune inhibitory receptors, such as PD-1, CTLA-4, Tim-3, and a progressive loss of function. The recent development of therapies targeting PD-1 and CTLA-4 have raised great interest since they induced long-lasting objective responses in patients suffering from advanced metastatic tumors. However, the regulation of PD-1 expression, and thereby of exhaustion, is unclear. VEGF-A, a proangiogenic molecule produced by the tumors, plays a key role in the development of an immunosuppressive microenvironment. We report in the present work that VEGF-A produced in the tumor microenvironment enhances expression of PD-1 and other inhibitory checkpoints involved in CD8+ T cell exhaustion, which could be reverted by anti-angiogenic agents targeting VEGF-A–VEGFR. In view of these results, association of anti-angiogenic molecules with immunomodulators of inhibitory checkpoints may be of particular interest in VEGF-A-producing tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have demonstrated that VEGF blockade can reverse T cell failure and enhance the therapeutic effect of ICI [59,60].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [59]
In the citing paper
“expression of co-inhibitory receptors, including PD-1 by CD8 + CTLs”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Voron et al., 2015
In the citing paper
“First, increased VEGF directly inhibits CTL trafficking, proliferation, and effector function22”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [22]
In the citing paper
“Secondly, VEGF could inhibit the maturation of DC, induce the exhaustion of T cells, promote the proliferation of Tregs, and increase the ratio of MDSCs [90–93].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“2015 Vol. 212 No. 2 139–148 www.jem.org/cgi/doi/10.1084/jem.20140559 139 Brief Definit ive Report One of the major processes involved in tumor appearance and growth is the capacity of tumor cells to develop escape mechanisms to the immune system (Schreiber et al., 2011).”
BackgroundInfluentialWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“The mechanisms involved in PD-1 expression and exhaustion of tumor-infiltrating T cells are poorly understood, even though a link to antigen persistence has been suggested (Wherry, 2011).”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · cited 1×
“In tumors or during chronic viral infections, PD-1 expression is maintained (Wherry et al., 2007).”
BackgroundTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 6×
“Cell surface-staining was performed on tumor-infiltrating cells using antiCD8 (53–6.7; eBioscience), anti–PD-1 (J43; eBioscience), anti–CTLA-4 (UC10-4B9; BioLegend), anti–Lag-3 (C9B7W; BioLegend), anti–Tim-3 (RMT3-23; BioLegend), anti–mouse VEGF-R2 (89B3A5; BioLegend), and anti–mouse VEGF-R1 (141522; R&D Systems).”
BackgroundInfluentialBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · cited 1×
“To determine whether VEGF-R1 or VEGF-R2 are involved in the T cells express these receptors the more they are dysfunctional (Blackburn et al., 2009).”
BackgroundGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Cited by
Items 601–700 of 1,000
Enhancing Colorectal Cancer Treatment Through VEGF/VEGFR Inhibitors and Immunotherapy
Jiao, J., Wu, Y., Wu, S., & Jiang, J. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01306-8 · Cited by 22
“…low VEGF-A expression, as well as in the ectopic and liver metastasis CT26 model with high VEGF-A expression, VEGF-A inhibition downregulated the combination of anti-PD-1 and VEGF-A blockade exhibits a synergistic enhancing effect, especially more pronounced in tumors with high VEGF-A levels[66].”
CD8+ T Cell Subsets as Biomarkers for Predicting Checkpoint Therapy Outcomes in Cancer Immunotherapy
Casalegno‐Garduño, R., Spitschak, A., Pannek, T., & Pützer, B. M. (2025) · Biomedicines · doi:10.3390/biomedicines13040930 · Cited by 21
“Inhibition of this pro-angiogenic pathway by VEGFR2 kinase blockade has been shown to be effective in various cancers [22], as it reduces immunosuppression by preventing the recruitment of immature dendritic cells (DCs), myeloid-derived suppressor cells (MDSCs), and Tregs [23,24].”
The Emerging Role of Immunotherapy in Gastric and Esophageal Adenocarcinoma
Bockorny, B., & Pectasides, E. (2016) · Future Oncology · doi:10.2217/fon-2016-0103 · Cited by 19
Système immunitaire et tumeurs
Terme, M., & Tanchot, C. (2017) · Annales de Pathologie · doi:10.1016/j.annpat.2016.12.004 · Cited by 19
Self-citationWei, Q., & Taskén, K. (2022) · Biochemical Journal · doi:10.1042/bcj20210233 · Cited by 19
Tregs are involved in VEGFA/ VASH1-related angiogenesis pathway in ovarian cancer
Qiao, S., Hou, Y., Rong, Q., Han, B., & Liu, P. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101665 · Cited by 17
Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
Carloni, R., Sabbioni, S., Rizzo, A., Ricci, A. D., Palloni, A., Petrarota, C., Cusmai, A., Tavolari, S., Gadaleta‐Caldarola, G., & Brandi, G. (2023) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s390963 · Cited by 20
“It is enough to say that either hypoxic environment or the vascular endothelial growth factor (VEGF) secreted by tumor-associated cells induce PD-L1 upregulation, hence resulting in tumor immuno-resistance.(16,17) Similarly, also the intrinsic mechanisms underpinning the tumor immune escape seem to be sustained by tyr…”
BackgroundA multidisciplinary approach with immunotherapies for advanced hepatocellular carcinoma
Lee, Y. R. (2023) · Journal of Liver Cancer · doi:10.17998/jlc.2023.09.04 · Cited by 18
“cell proliferation and cytotoxic activity by these factors also contribute to T cell exhaustion.(31) VEGF blocking enhances”
Yi, C., Bian, D., Wang, J., Hu, S., Sun, L., Yan, Y., Wang, S., Shen, Z., Yu, H., Yang, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57184-z · Cited by 22
“Many studies have shown that VEGF inhibitors exert an immune-enhancing effect 19 , and several preclinical studies have shown that immunotherapy plus VEGF-targeted therapy can enhance the effectiveness of immunotherapy 20,21 .”
Salazar, M. D., Manuel, E. R., Tsai, W., D’Apuzzo, M., Goldstein, L., Blazar, B. R., & Diamond, D. J. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1160184 · Cited by 16
“In addition, VEGF-A was shown to have broad effects in inhibiting MDSC differentiation and inducing PD1 expression on CD8C T cells.(24,25) These results suggest that inhibition of PD1 modulates cytokine expression in the TME within a few days after administration.”
BackgroundNoé, G., Bellesœur, A., Thomas‐Schoemann, A., Rangarajan, S., Naji, F., Puszkiel, A., Huillard, O., Saidu, N. E. B., Golmard, L., Alexandre, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11686 · Cited by 17
“A recent study showed that the plasma level of VEGF-A was 3- to 4-fold higher in mRCC patients than in healthy volunteers [25].”
BackgroundAdvancing Immunotherapy in Metastatic Breast Cancer
Mansour, M., Teo, Z. L., Luen, S. J., & Loi, S. (2017) · Current Treatment Options in Oncology · doi:10.1007/s11864-017-0478-9 · Cited by 19
Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis
Seijkens, T. T. P., & Lutgens, E. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000538 · Cited by 18
“treatment, which enhances IFNg-driven Th1 responses [16,21,25].”
BackgroundTargeting Angiogenesis With Peptide Vaccines
Rahat, M. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01924 · Cited by 19
Cutmore, L. C., Brown, N. F., Raj, D., Chauduri, S., Wang, P., Maher, J. F., Wang, Y., Lemoine, N. R., & Marshall, J. F. (2020) · Pancreatology · doi:10.1016/j.pan.2020.02.006 · Cited by 22
Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy
Dong, Y., Gao, J., Pei, M., Wang, X., Zhang, C., Du, Y., & Jiang, Y. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s242463 · Cited by 17
Association of BTLA rs1982809 polymorphism with lung cancer risk in Tunisian population
Khadhraoui, C., Kaabachi, W., Tritar, F., Daghfous, H., Hamzaoui, K., & Hamzaoui, A. (2020) · International Journal of Immunogenetics · doi:10.1111/iji.12491 · Cited by 19
Matsumoto, K., Shiroyama, T., Kuge, T., Miyake, K., Yamamoto, Y., Yoneda, M., Yamamoto, M., Naito, Y., Suga, Y., Fukushima, K., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.11.008 · Cited by 18
Drug Repurposing at the Interface of Melanoma Immunotherapy and Autoimmune Disease
Spitschak, A., Gupta, S. K., Singh, K. P., Logotheti, S., & Pützer, B. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010083 · Cited by 20
“In addition to macrophages, aspirin also exerts an immunomodulatory function on other immune cells such as MDSCs and Tregs [101], overall proposing aspirin as an attractive agent for combination therapies.”
BackgroundInfluentialHost-directed therapies for antimicrobial resistant respiratory tract infections
Maeurer, M. J., Rao, M., & Zumla, A. I. (2016) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000271 · Cited by 17
Newly developed anti-angiogenic therapy in non-small cell lung cancer
Qu, J., Zhang, Y., Chen, X., Yang, H., Zhou, C., & Yang, N. (2017) · Oncotarget · doi:10.18632/oncotarget.23755 · Cited by 18
“It is reported that sunitinib decreased PD-1 expression and increased the infiltration of CD-4+ T cells into the tumor [64].”
BackgroundVeldman, J., Alsada, Z. N. D., van den Berg, A., Plattel, W. J., Diepstra, A., & Visser, L. (2021) · British Journal of Haematology · doi:10.1111/bjh.17362 · Cited by 17
“VEGF induced PD-1 expression on CD8+ T cells in mouse models of colon cancer.(14) In HL, VEGF is expressed by both HRS cells and TAMs.”
BackgroundResultAnti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy
Ishikawa, E., Miyazaki, T., Takano, S., & Akutsu, H. (2021) · Brain Tumor Pathology · doi:10.1007/s10014-021-00402-5 · Cited by 21
Zhang, Z., & Wu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1641518 · Cited by 21
Stühler, V., Rausch, S., Maas, J. M., Stenzl, A., & Bedke, J. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1890713 · Cited by 18
Clinical applicability of renin-angiotensin system inhibitors in cancer treatment.
Jiang, H., Tai, Z., Chen, Z., Zhu, Q., & Bao, L. (2021) · American Journal of Cancer Research · Cited by 25
Shi, Y., Li, Y., Wu, B., Zhong, C., Lang, Q., Liang, Z., Zhang, Y., Lv, C., Han, S., Yu, Y., et al. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108968 · Cited by 17
Zhang, Y., Huang, Y., Yang, Y., Zhao, Y., Zhou, T., Chen, G., Zhao, S., Zhou, H., Ma, Y., Hong, S., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01974-2 · Cited by 21
Wu, J., Zhang, S., Yu, S., An, G., Wang, Y., Yu, Y., Liang, L., Wang, Y., Xu, X., Xiong, Y., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53109-4 · Cited by 19
Burmeister, K., Quagliata, L., Andreozzi, M., Eppenberger‐Castori, S., Matter, M. S., Perrina, V., Grobholz, R., Jochum, W., Horber, D., Moosmann, P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175563 · Cited by 17
El-Osta, H. E., Mott, F. E., Burt, B. M., Wang, D. Y., & Sabichi, A. L. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1665974 · Cited by 16
“Reportedly, VEGF blockade may result in a less-immunosuppressive microenvironment.(24,25) Moreover, VEGF is believed to mediate resistance to EGFR inhibitors.”
BackgroundTanimura, K., Yamada, T., Omura, A., Shiotsu, S., Kataoka, N., Takeda, T., Taniguchi, R., Yamada, T., Takeuchi, M., Chihara, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.663612 · Cited by 16
“VEGF/VEGFR signaling promotes evasion of the antitumor immune response through multiple mechanisms, including suppression of dendritic-cell maturation (8), reducing cytotoxic T lymphocyte activity via production of inflammatory cytokines and upregulation of immune checkpoint expression (9, 10), activation of regulator…”
BackgroundLim, J., Puan, K. J., Wang, L. W., Teng, K. W. W., Loh, C. Y., Tan, K. P., Carissimo, G., Chan, Y., Poh, C. M., Lee, C. Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.710217 · Cited by 21
Endothelial epsins as regulators and potential therapeutic targets of tumor angiogenesis
Song, K., Wu, H., Rahman, H. N. A., Dong, Y., Wen, A., Brophy, M. L., Wong, S., Kwak, S., Bielenberg, D. R., & Chen, H. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2347-2 · Cited by 18
“Given that VEGF action has emerged as a potent immunoinhibitory factor as evidenced by its modulation of expression of inhibitory checkpoints on T cells in tumors (also mediated by VEGFR2 on T cells), whether the epsin mimetic peptide could also enhance adaptive anti-tumor immunity is of special interest [54, 55].”
The crossroad between tumor and endothelial cells
Ribatti, D. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01490-1 · Cited by 21
“VEGFA promotes the expression of PD-1, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), TIM3, and lymphocyte activation gene 3 protein [53].”
BackgroundSecretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency
Supper, V. M., Donner, H., Birocchi, F., Bratt, A., Escobar, G., Kann, M. C., Park, S., Martin, G., Korell, F., Takei, H., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0876 · Cited by 17
Meyer, P., Savard, M., Poirier, J., Morgan, D., Breitner, J. C. S., & Initiative, A. D. N. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.05.007 · Cited by 16
“Although important to vascular homeostasis [58], VEGF has been shown also to induce microglial chemotaxis and proliferation [59,60] and to be an important mediator of the immune response to tumors [61].”
BackgroundTumor Angiocrine Signaling: Novel Targeting Opportunity in Cancer
Oria, V. O., & Erler, J. T. (2023) · Cells · doi:10.3390/cells12202510 · Cited by 20
“Crosstalk between immune cells and endothelial cells determines the fate of anti-tumor immunity and the efficacy of immunotherapy [2,6,28,72,73].”
BackgroundZheng, Y., Xiang, Y., Shi, H., Lin, Z., Cheng, S., & Zhu, J. (2024) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s461630 · Cited by 20
“36 These studies also provide a theoretical basis for the superiority of combined TACE treatment with Atez/Bev over TACE alone.”
BackgroundTackling Resistance to Cancer Immunotherapy: What Do We Know?
Gondhowiardjo, S. A., Handoko, H., Jayalie, V. F., Apriantoni, R., barata, A. R., Senoaji, F., Utami, I. J. W., Maubere, F., Nuryadi, E., & Giselvania, A. (2020) · Molecules · doi:10.3390/molecules25184096 · Cited by 18
Palle, J., Hirsch, L., Lapeyre-Prost, A., Malka, D., Bourhis, M., Pernot, S., Marcheteau, E., Voron, T., Castan, F., Lacotte, A., et al. (2021) · Cancers · doi:10.3390/cancers13215562 · Cited by 17
“We and others have previously shown that VEGF-A, a proangiogenic factor, has an immunomodulatory role since it can elicit the accumulation of Treg and myeloidderived suppressor cells, inhibit the maturation of dendritic cells and induce the expression of immune checkpoints on CD8+ T cells in tumor-bearing hosts [2,40,…”
BackgroundSelf-citationThe Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?
Puzzoni, M., Silvestris, N., Leone, F., Giampieri, R., Faloppi, L., Demurtas, L., Dell’Aquila, E., Marino, D., Brunetti, O., Garattini, S. K., et al. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0437-6 · Cited by 15
“The vascular endothelial growth factor A (VEGF-A) showed an immunosuppressive effect in preclinical models through the induction of inhibitory checkpoints, such as PD1 [102].”
BackgroundInfluentialPresti, V. L., Nierkens, S., Boelens, J. J., & van Til, N. P. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1431119 · Cited by 18
“In the preliminary stages of this process, T cells may be hampered to efficiently home the tumor environment due to interference with attractive chemokines – that is, mainly chemokine (C-X-C motif) ligand (CXCL) 9, 10 and 11 [85] and/or production of vascular endothelial growth factor (VEGF) [86,87].”
BackgroundGenetic variation determines VEGF-A plasma levels in cancer patients
Innocenti, F., Jiang, C., Sibley, A. B., Etheridge, A. S., Hatch, A. J., Denning, S., Niedzwiecki, D., Shterev, I. D., Lin, J., Furukawa, Y., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-34506-4 · Cited by 15
Unlocking new horizons in oncology: ivonescimab’s dual-target approach to anti-VEGF/PD-1(L1) therapy
Shi, F., Yang, L., Gao, Y., Hou, Y., Lv, Q., Cao, F., Chen, X., Zhang, J., & Wang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1599181 · Cited by 19
Hua, Y., Dong, R., Jin, T., Jin, Q., & Chen, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.781348 · Cited by 15
The future is now: beyond first line systemic therapy in hepatocellular carcinoma
Nenu, I., Breaban, I., Pascalau, S., Bora, C.-N., & Ştefănescu, H. (2019) · Translational Cancer Research · doi:10.21037/tcr.2018.11.23 · Cited by 15
“VEGF promotes the expression of PD-1 and CTLA-4 by inducing CD8 T cells’ exhaustion (108).”
BackgroundSkolastika, S., Hanif, N., Ikawati, M., & Hermawan, A. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/4172531 · Cited by 17
“HDAC1 suppression has been reported to reduce the invasion of breast cancer cells by inhibiting matrix metalloproteinase-9, [67] and to reduce PD-L1 and HLA-DR expression and Treg frequency in triple negative breast cancer [68].”
BackgroundTargeted and cellular therapies in lymphoma: Mechanisms of escape and innovative strategies
Deshpande, A. J., & Munoz, J. L. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.948513 · Cited by 17
“This, in turn, leads to T-cell exhaustion (31).”
BackgroundInfluentialAngiogenic inhibitor pre‐administration improves the therapeutic effects of immunotherapy
Sato, M., Maishi, N., Hida, Y., Yanagawa‐Matsuda, A., Alam, M. T., Sakakibara‐Konishi, J., Nam, J., Onodera, Y., Konno, S., & Hida, K. (2023) · Cancer Medicine · doi:10.1002/cam4.5696 · Cited by 13
Baggio, C., Ramaschi, G. E., Oliviero, F., Ramonda, R., Sfriso, P., Trevisi, L., Cignarella, A., & Bolego, C. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114670 · Cited by 14
Nevola, R., Femine, A. D., Rosato, V., Kondili, L. A., Alfano, M., Mastrocinque, D., Imbriani, S., Perillo, P., Beccia, D., Villani, A., et al. (2023) · Cancers · doi:10.3390/cancers15112950 · Cited by 15
“However, by reducing VEGF-induced immunosuppression, anti-VEGF therapies are able to improve the efficacy of anti-PD-1 and anti-PD-L1 treatments [31,32].”
BackgroundClinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy
Meo, C., & de Nigris, F. (2024) · Cancers · doi:10.3390/cancers16030491 · Cited by 14
“Nonetheless, some challenges remain, as the effective dose, timing, and duration of treatment need to be established, but studies evaluating the effects of different strategies are beginning to emerge [104].”
BackgroundRen, S., Lu, Y., Zhang, G., Xie, K., Chen, D., Cai, X., & Ye, M. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05976-0 · Cited by 14
Croci, D. O., Méndez‐Huergo, S. P., Cerliani, J. P., & Rabinovich, G. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_29 · Cited by 16
Immunotherapy in colorectal cancer treatment: actual landscape and future perspectives
Bittoni, A., Sotte, V., Meletani, T., Cantini, L., Giampieri, R., & Berardi, R. (2018) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2018.37 · Cited by 15
“Vascular endothelial growth factor-A (VEGF-A), a proangiogenic molecule produced by the tumors, has a crucial role in the development of the immunosuppressive microenvironment([39]).”
BackgroundSaha, A., & Anirvan, P. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1099 · Cited by 16
“• COVID-19: coronavirus disease 2019 • SARS-CoV2: severe acute respiratory syndrome coronavirus 2 • RAAS: renin angiotensin aldosterone system • AT: angiotensin • AT II: angiotensin 2 • AT-R: angiotensin receptor • ACE: angiotensin converting enzyme • MasR: Mas receptor • TME: tumour micro-environment • ECM: extracell…”
BackgroundInfluentialZhang, E., Zhang, Z.-Y., Li, J., & Huang, Z. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s284092 · Cited by 14
Mooi, J. K., Chionh, F. J. M., Savas, P. S., Duarte, J. D. G., Chong, G., Brown, S. C., Wong, R., Price, T. J., Wann, A., Skrinos, E., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2714 · Cited by 18
“Furthermore, VEGF promotes immune tolerance in tumors by establishing an immune barrier in the endothelium and enhancing expression of inhibitory checkpoints, such as PD-1, in tumor-infiltrating T cells (29, 30).”
BackgroundIshihara, H., Kondo, T., Nakamura, K., Nemoto, Y., Tachibana, H., Fukuda, H., Yoshida, K., Kobayashi, H., Iizuka, J., Shimmura, H., et al. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab142 · Cited by 14
The immune landscape of hepatocellular carcinoma‑where we are? (Review)
Gryziak, M., Woźniak, K., Kraj, L., Róg, L., & Stec, R. (2022) · Oncology Letters · doi:10.3892/ol.2022.13530 · Cited by 18
“VEGF‐A produced in the tumor microenvironment enhances the expression of PD‐1 and other inhibitory checkpoints involved in CD8+ T‐cell exhaustion, and this could be inhibited using anti‐angiogenic agents targeting VEGF‐A and/or VEGFR (69).”
BackgroundDelcuratolo, M. D., Tucci, M., Turco, F., Stefano, R. F. D., Ungaro, A., Audisio, M., Samuelly, A., Brusa, F., Audisio, A., Maïo, M. D., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103881 · Cited by 13
Mechanisms of drug resistance in breast cancer liver metastases: Dilemmas and opportunities
Yan, C., Zhao, M., Wei, Y.-N., & Zhao, X. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.02.001 · Cited by 16
“28 March 2023 icant reduction in tumorburdenwhen the treatmentwas combinedwith VEGF inhibitors.(44) This suggests that VEGF-A-producing liver tumors may benefit from association of anti-angiogenic molecules with immunomodulators of inhibitory checkpoints.”
BackgroundTreatment options after first-line immunotherapy in metastatic NSCLC
Santos, E. S. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1738930 · Cited by 14
Avelumab: search for combinations of immune checkpoint inhibition with chemotherapy
Hamilton, G. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1825679 · Cited by 15
Ishi, A., Tanaka, I., Iwama, S., Sakakibara, T., Mastui, T., Kobayashi, T., Hase, T., Morise, M., Sato, M., Arima, H., et al. (2021) · Endocrine Journal · doi:10.1507/endocrj.ej20-0769 · Cited by 14
“A combination of ICIs and anti-vascular endothelial growth factor (VEGF) therapies has synergistic biological effects to improve the tumor microenvironment [19-21].”
BackgroundHuang, Z., Li, L., Zhao, X., Jin, H., Shen, M., Li, B., Zeng, Y., Zhang, Q., Wang, Q., Wang, M., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06485-4 · Cited by 13
“Moreover, growth factors such as VEGFA reduce the adhesion and migration of immune cells [8], inhibit the maturation and the differentiation of hematopoietic precursor cells [9], and promote the expression of immune checkpoint ligand in CD8 + T cell [10].”
Unlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype
Desimpel, P.-H., Petit, P.-F., den Eynde, B. J. V., & Zhu, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1708873 · Cited by 23
“VEGF has been shown to enhance the expression of several immune checkpoints including PD-1 on the surface of CD8 + T cells in tumors (83), while inducing PD-L1 expression by various cellular components of the TME including endothelial cells (84).”
CD8+ T Cells in Immunotherapy, Radiotherapy, and Chemotherapy
Wang, W., Green, M. D., Liu, J. R., Lawrence, T. S., & Zou, W. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_3 · Cited by 21
Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer
Hawlina, S., Zorec, R., & Chowdhury, H. H. (2023) · Life · doi:10.3390/life13071498 · Cited by 13
“In such conditions, immunosuppressive cell populations are recruited, and the function of antitumor effector CD8+ T lymphocytes and DCs is inhibited [152,153].”
BackgroundDrug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy
To, K. K. W., & Cho, W. C. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082166 · Cited by 18
“Inhibition of VEGFR2 was reported to prevent the recruitment of immature dendritic cells, MDSC, and Tregs, thereby abolishing the immunosuppressive TME [52,53].”
BackgroundEndocrine immune-related adverse effects of immune-checkpoint inhibitors
Trevisani, V., Iughetti, L., Lucaccioni, L., & Predieri, B. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2256841 · Cited by 18
Adkins, D., Ley, J. C., Liu, J., & Oppelt, P. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00204-3 · Cited by 17
Toshida, K., Itoh, S., Iseda, N., Tanaka, S., Nakazono, K., Tomiyama, T., Yoshiya, S., Toshima, T., Harada, N., Kohashi, K., et al. (2024) · Liver Cancer · doi:10.1159/000540180 · Cited by 21
Zhang, X., Deng, X., Tan, J., Liu, H., Zhang, H., Li, C., Li, Q., Zhou, J., Xiao, Z., & Li, J. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101343 · Cited by 16
Aspeslagh, S., Awada, A. H., Matos-Pita, A. S., Aftimos, P. G., Bahleda, R., Varga, A., & Soria, J. (2016) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000409 · Cited by 13
Yun, J.-A., Kim, J., Baek, Y.-Y., Park, W., Park, M., Kim, S., Kim, T., Choi, S., Jeoung, D., Lee, H., et al. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.117234 · Cited by 14
“An interesting study showed that VEGF-A enhances the expression of PD-1 and other inhibitory checkpoints involved in CD8(1) T-cell exhaustion (Voron et al., 2015), which suggests”
BackgroundHu, J., Wang, Z., Chen, Z., Li, A., Sun, J. P., Zheng, M., Wu, J., Shen, T., Qiao, J., Li, L., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110229 · Cited by 15
Tokumasu, M., Nishida, M., Kawaguchi, T., Kudo, I., Kotani, T., Takeda, K., Yoshida, T., & Udono, H. (2022) · International Immunology · doi:10.1093/intimm/dxac004 · Cited by 15
Ruan, L., Zhang, S., Chen, X., Liang, W., & Xie, Q. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153956 · Cited by 14
Baci, D., Cekani, E., Imperatori, A. S., Ribatti, D., & Mortara, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.914890 · Cited by 13
Zhang, B., Tao, B., Li, Y., Yi, C., Lin, Z., Ma, Y., Han, J., Shao, W., Chen, Z., Lin, J., et al. (2022) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2022.12.025 · Cited by 16
Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy
Pang, L., Gan, J., Huang, Y., Liao, J., Zhuang, W., Ali, W. A. S., Hong, S., Zhang, L., & Fang, W. (2023) · BMC Cancer · doi:10.1186/s12885-022-10446-1 · Cited by 13
“Anti-PD-1 and anti-CTLA-4 antibody are ICIs with distinct but complementary mechanisms of action.”
BackgroundInfluentialYang, Z., Guo, J., Cui, K., Du, Y., Zhao, H., Zhu, L., Weng, L., Tang, W., Guo, J., Zhāng, T., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110740 · Cited by 14
Oudard, S. M., Benhamouda, N., Escudier, B. J., Ravel, P., Tran, T., Levionnois, É., Négrier, S., Barthélémy, P., Berdah, J. F., Gross‐Goupil, M., et al. (2021) · Cells · doi:10.3390/cells11010017 · Cited by 17
Self-citationDurvalumab: an investigational agent for unresectable hepatocellular carcinoma
Maestri, M., Pallozzi, M., Santopaolo, F., Cerrito, L., Pompili, M., Gasbarrini, A., & Ponziani, F. R. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2033208 · Cited by 13
“Furthermore, VEGF induces the expression of Fas ligand on endothelial cells of tumor vessels that become able of killing CD8+ T cells, and upregulates PD-1 expression through the VEGFR2-polycystin-1 (PLCy)-calcineurin-nuclear factor of activated T-cells (NFAT) pathway [94,95].”
Lenvatinib enhances antitumor immunity of anti-PD-1 antibody
Kato, Y. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02721-5 · Cited by 13
“…of activated CD8 + T-cells by enhancing the expression of immune checkpoint molecules, including PD-1, CTLA-4, and LAG-3, and anti-VEGFA antibody decreases the expression of immune checkpoint molecules which lead to suppression of tumor growth in anti-PD-1 antibody-resistant tumor models [28].”
Wang, Z., Shi, X., Zhao, Y., Zhou, J., Zhang, S., Wang, J., Yu, W., Zhang, X., Ren, X., & Zhao, H. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.04.018 · Cited by 13
Isthmin: A multifunctional secretion protein
Liang, J.-Y., Wei, H., & Tang, Y. (2023) · Cytokine · doi:10.1016/j.cyto.2023.156423 · Cited by 12
Lentz, R. W., Friedrich, T. J., Blatchford, P. J., Jordan, K. R., Pitts, T. M., Robinson, H. R., Davis, S. L., Kim, S. S., Leal, A. D., Lee, M. R., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0090 · Cited by 13
Zeng, Z., & Zhu, Q. C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1382183 · Cited by 12
Lin, X., Wei, R., Xu, Z., Zhuo, S., Dou, J., Sun, H., Li, R., Yang, R., Lü, Q., An, C., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102808 · Cited by 12
“25 Finally, for patients predicted to exhibited OOR to initial IAITs only, our fi ndings would be able to caution against anticipating subsequent targeted-immunotherapy or molecular targeted agent to avoid potential economic loss and complications.”
Lin, Q.-X., Song, W.-W., Xie, W.-X., Deng, Y., Gong, Y.-N., Liu, Y., Tian, Y., Zhao, W.-Y., Tian, L., & Gu, D.-N. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101077 · Cited by 14
Overcoming immune evasion with innovative multi-target approaches for glioblastoma
Su, H., Peng, Y., Wu, Y.-L. L. C., & Zeng, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1541467 · Cited by 18
Wang, F., Wei, X., Zheng, Y., Wang, J., Ying, J., Chen, X., Luo, S., Luo, H., Yu, X., Chen, B., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.70653 · Cited by 14
Angiogenesis and immune microenvironment in triple-negative breast cancer: Targeted therapy
Zhang, Y., Yang, H., Jiang, Y., Jiang, Y., & Mao, R. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167880 · Cited by 17
Sergio Bracarda, A., Porta, C., Sabbatini, R., & Rivoltini, L. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.07.009 · Cited by 12
Nanoenabled Tumor Oxygenation Strategies for Overcoming Hypoxia-Associated Immunosuppression
Zhang, C., Yan, Q., Li, J., Zhu, Y. J., & Zhang, Y. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01328 · Cited by 12
Tannir, N. M., Hammers, H. J., & Amin, A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1423960 · Cited by 15
Metadata
- Authors
- Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., Stockmann, C., Combe, P., Berger, A., Zinzindohoue, F., Yagita, H., Tartour, E., Taieb, J., & Terme, M.
- Affiliations
- Inserm (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Service d’immunologie biologique 2 , 3 , 4 , 5
- Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan 6
- INSERM U970, Paris Cardiovascular Research Center, Université Paris-Descartes, Sorbonne Paris Cité, 75015 Paris, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-01-19
- Volume
- 212
- Issue
- 2
- Pages
- 139-148
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4322048
- OpenAlex
- W2156906256
- Cited by
- 1,179
- References
- 32
- Citations by year
- 2026: 81 · 2025: 100 · 2024: 121 · 2023: 142 · 2022: 169 · 2021: 147 · 2020: 127 · 2019: 92 · 2018: 81 · 2017: 51 · 2016: 50 · 2015: 16
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Ligue Contre le Cancer
- Assistance publique-Hôpitaux de Paris
- Fonds d’Etudes et de Recherche du Corps Médical
- Japan Society for the Promotion of Science (26290059)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- VEGF-A, PD-1, CTLA-4, TIM-3, CD8+ T cell exhaustion, tumor immune evasion, tumor microenvironment, anti-angiogenic therapy, VEGFR inhibition, immune checkpoint inhibitors, cancer immunotherapy
- MeSH terms
- Animals, Disease Models, Animal, Female, Neoplasms, Protein Binding, Signal Transduction, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Gene Expression Profiling, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Mice, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.